help button home button Am J Pathol R & D Systems
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cui, H.
Right arrow Articles by Ding, H.-F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cui, H.
Right arrow Articles by Ding, H.-F.
(American Journal of Pathology. 2007;170:1370-1378.)
© 2007 American Society for Investigative Pathology
DOI: 10.2353/ajpath.2007.060754

Bmi-1 Is Essential for the Tumorigenicity of Neuroblastoma Cells

Hongjuan Cui*, Bo Hu{dagger}, Tai Li*, Jun Ma*, Goleeta Alam*, William T. Gunning* and Han-Fei Ding*

From the Department of Biochemistry and Cancer Biology,* Medical University of Ohio, Toledo, Ohio; and the Department of Neurology,{dagger} Union Hospital, Huazhong University of Science and Technology, Wuhan, China

Activation of oncogenes underlies the pathogenesis of most human cancers. In neuroblastoma, amplification of the oncogene MYCN occurs in ~22% of cases and is associated with advanced stages of the disease and poor prognosis. Identification of other oncogenes that are consistently mutated or overexpressed in neuroblastoma is crucial for a molecular understanding of the pathogenic process. Here, we report that the oncogene Bmi-1 is highly expressed in human neuroblastoma cell lines and primary tumors. Neuroblastoma development in MYCN transgenic mice, an animal model for the human disease, was associated with a marked increase in the levels of Bmi-1 expression. Bmi-1 cooperated with MYCN in transformation of benign S-type neuroblastoma cells and avian neural crest cells by inhibiting the apoptotic activity of MYCN. Importantly, down-regulation of Bmi-1 impaired the ability of neuroblastoma cells to grow in soft agar and induce tumors in immunodeficient mice. Moreover, Bmi-1-knockdown neuroblastoma xenografts were characterized by a significant increase in the amount of Schwannian stroma, a histological feature associated with clinically favorable neuroblastomas. These findings suggest a crucial role for Bmi-1 in neuroblastoma pathogenesis and provide insights into the molecular basis of neuroblastoma heterogeneity.




This article has been cited by other articles:


Home page
 Cancer Res.Home page
D. Douglas, J. H.-R. Hsu, L. Hung, A. Cooper, D. Abdueva, J. van Doorninck, G. Peng, H. Shimada, T. J. Triche, and E. R. Lawlor
BMI-1 Promotes Ewing Sarcoma Tumorigenicity Independent of CDKN2A Repression
Cancer Res., August 15, 2008; 68(16): 6507 - 6515.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Yang, L. Chai, C. Gao, T. C. Fowles, Z. Alipio, H. Dang, D. Xu, L. M. Fink, D. C. Ward, and Y. Ma
SALL4 is a key regulator of survival and apoptosis in human leukemic cells
Blood, August 1, 2008; 112(3): 805 - 813.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. J. Lee, J. Dosch, and D. M. Simeone
Pancreatic Cancer Stem Cells
J. Clin. Oncol., June 10, 2008; 26(17): 2806 - 2812.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Society for Investigative Pathology.